Skip to main content
. 2024 May 10;15(5):607. doi: 10.3390/genes15050607

Figure 2.

Figure 2

Adjusted incidence (based on the fully balanced data in Table 3) of ischemic and bleeding events in clopidogrel-treated patients with different CYP2C19 phenotypes: poor (PM), intermediate (IM), normal (NM), rapid (RM), or ultrarapid (UM) metabolizer. Depicted are percentages from the weighted pseudopopulations.